SCD147: EMMPRIN(EXTRACELLULAR MATRIX METALLOPROTIENASE INDUCER) AS TUMOUR MARKER FOR BLADDER CARCINOMA.

Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Title: sCD147: EMMPRIN(extracellular matrix metalloprotienase inducer) as tumour marker for bladder carcinoma Background: A new marker sCD147 also known as (EMMPRIN extracellular matrix metalloprotienase inducer), tumor collagenase stimulatory factor (TCSF), Hab 18 G, OX- 47, Neurothelin, Basigin is a cell surface protein which is broadly expressed on human peripheral blood cells, endothelial cells, cultured cells of hemopiotic and non hemopioticorgin. In T cells its expression level is dependent on differentiation state. Thymocytes strongly expresses sCD14, significant expression of sCD147 has also been reported in neoplasms of urinary bladder, liver and lung. Study Design: Hospital based prospective study Aim: To evaluate the clinical signifance of sCD147 as a tumor marker for the diagnosis and postoperative follow up of patients suffering from bladder cancer. Method: Serum samples collected from 33 bladder cancer patients in preoperative and 3- 5 months postoperative period were subjected to solid phase enzyme linked immunosorbent assay (ELISA) based on sandwich principle and serum concentration level of sCD147 was compared between preoperative and postoperative. Results: Mean preoperative and postoperative sCD147 levels were compared and showed significant results(p<0.05). Conclusion: It was concluded from this study that sCD147 levels are high in bladder cancer patients and decrease after resection (TURBT) to significant levels at 3-5 months. Thus sCD147 could be one of the prognostic factors in bladder carcinoma as is described in other studies too, and can be a useful marker in the postoperative period in patients with bladder carcinoma.

  1. Arshad A Pandith, Zaffar A Shah, Nighat P Khan, Mohammad S Wani, AdfarYousuf, RoohiRasool, DilAfroze, Mushtaq A Siddiqi; FGFR3 germ line mutations identified in skeletal dysplasia significantly cause low grade and low stage bladder cancer by somatic mutations.UrotodayInt journal 2010; 3(6).
  2. Lotan Y, Roehrborn C G, “Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach”, Urol. 2002; 167: pp. 75–79.
  3. Iacono KT, Brown AL, Greene MI, et al: CD147 immunoglobulin superfamily receptor function and role in pathology. ExpMolPathol 2007 83 (3) :283-295.
  4. Fisher MR, Hricak H, Tanagho EA: Urinary bladder MR imaging. Radiology 1985;157:471.
  5. Wood DP et al: The role of magnetic resonance imaging in the staging of bladder carcinoma. J Urol 1988;140:741.
  6. Kirsch, A.H., Diaz, L.A.J., Bonish, B., Antony, P.A. and Fox, D.A: The pattern of expression ofCD147/neurothelin during human T-cell ontogeny as defined by the monoclonal antibody 8D6.TissueAntigens 1997 50: 147-152.
  7. Muraoka, K., Nabeshima, K., Murayama, T., Biswas, C. and Koono, M: Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers. J. Cancer 1993 55: 19-26.
  8. Fisher MR, Hricak H, Tanagho EA: Urinary bladder MR imaging. Radiology 1985;157:471.
  9. Wood DP et al: The role of magnetic resonance imaging in the staging of bladder carcinoma. J Urol 1988;140:741.
  10. Jocham D et al: Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 2005;174:862.
  11. Iacono KT, Brown AL, Greene MI, et al: CD147 immunoglobulin superfamily receptor function and role in pathology. ExpMolPathol 2007 83 (3) :283-295.
  12. Huet E, Gabison EE and Mourah S: Role of emmprin/CD147 in tissue remodeling. Connect Tissue Res 49: 175-179, 2008.
  13. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J and Kikuchi M: Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression.PatholInt56: 359-367, 2006.
  14. Gabison EE, Hoang-Xuan T, Mauviel A and Menashi S: EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair.Biochimie87: 361-368, 2005.
  15. Muramatsu T and Miyauchi T: Basigin (CD147): A multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. HistolHistopathol18: 981-987, 2003.
  16. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, SchueningF,Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM,
  17. Kasinrerk W, Fiebiger E, Stefanova I, Baumruker T, Knapp W and Stockinger H: Human leukocyte activation antigen M6, a member of the Igsuperfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. J Immunol149: 847-854, 1992.
  18. Altruda F, Cervella P, Gaeta ML, Daniele A, Giancotti F, Tarone G, Stefanuto G and Silengo L: Cloning of cDNA for a novel mouse membrane glycoprotein (gp42): shared identity to histocompatibility antigens, immunoglobulins and neural-cell adhesion molecules. Gene 85: 445-451, 1989.
  19. Miyauchi T, Kanekura T, Yamaoka A, Ozawa M, Miyazawa S and Muramatsu T: Basigin, a new, broadly distributed member of the immunoglobulin superfamily, has strong homology with both the immunoglobulin V domain and the beta-chain of major histocompatibility complex class II antigen.J Biochem107: 316- 323, 1990.
  20. Seulberger H, Lottspeich F and Risau W: The inducible blood rain barrier specific molecule HT7 is a novel immunoglobulin like cell surface glycoprotein. EMBO J 9: 2151-2158, 1990.
  21. Fossum S, Mallett S and Barclay AN: The MRC OX-47 antigen is a member of the immunoglobulin superfamily with an unusual transmembrane sequence. Eur J Immunol21: 671-679, 1991.
  22. Ochrietor JD, Moroz TP, van Ekeris L, Clamp MF, Jefferson SC, deCarvalho AC, Fadool JM, Wistow G, Muramatsu T and Linser PJ: Retina-specific expression of 5A11/Basigin-2, a member of the immunoglobulin gene superfamily. Invest Ophthalmol Vis Sci44: 4086-4096, 2003.
  23. Kataoka H, DeCastro R, Zucker S and Biswas C: Tumor cell derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 53: 3154-3158, 1993.
  24. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H and Nabeshima K: The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434-439, 1995.
  25. Guo H, Zucker S, Gordon MK, Toole BP and Biswas C: Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J BiolChem272: 24-27, 1997.
  26. Simpson RJ, Jensen SS and Lim JW: Proteomic profiling of exosomes: current perspectives. Proteomics 8: 4083-4099, 2008.
  27. Menashi S, Serova M, Ma L, Vignot S, Mourah S and Calvo F: Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res 63: 7575-7580, 2003.
  28. Han ZD et al: Expression and clinical significance of CD147 in genitourinary carcinomas.JSurg Res.2010 may 15;160(2)260-7).
  29. Nawroth et al: CD147(EMMPRIN):A potential therapeutic and prognostic markers in bladder cancer. Patholge.2010 oct;31suppl 2;251-4).
  30. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin2005; 55:10-30.
  31. Morrison AS: Advances in the etiology of urothelial cancer.UrolClin North Am 1984; 11:557.
  32. Varkarakis MJ, Gaeta J, Moore RH, et al. Superficial bladder tumor: Aspects of clinical progression.Urology1974; 4:41 Han ZD et al: Expression and clinical significance of CD147 in genitourinary carcinomas.JSurg Res.2010 may 15;160(2)260-7).
 

[Seth mujtaba, Perveez ahmad malik, Adil pervaiz shah, Baldev singh wazir, Qurat Ul ain and zafar amin shah. (2017); SCD147: EMMPRIN(EXTRACELLULAR MATRIX METALLOPROTIENASE INDUCER) AS TUMOUR MARKER FOR BLADDER CARCINOMA. Int. J. of Adv. Res. 5 (Jan). 2129-2137] (ISSN 2320-5407). www.journalijar.com

dr adil pervaiz shah
senior residant

DOI:

Article DOI: 10.21474/IJAR01/2987      
DOI URL: https://dx.doi.org/10.21474/IJAR01/2987

Download Full Paper

Download PDF No. of Downloads: 18 | No. of Views: 126